2601P Peripheral and tumor cytokines in exceptional responders to immunotherapy: Results from a phase III trial
R.M. Saliby(Dana-Farber Cancer Institute), Toni K. Choueiri(Harvard University), Karl Semaan(Broad Institute), D.A. Braun(Yale Cancer Center), Marc Machaalani(Dana-Farber Cancer Institute), Eddy Saad(Dana-Farber Cancer Institute), Sachet A. Shukla(The University of Texas MD Anderson Cancer Center), Clara Steiner(Dana-Farber Cancer Institute), Emre Yekedüz(Dana-Farber Cancer Institute), Marc Eid(Harvard University), R. Rout(Yale Cancer Center), Tejas Jammihal(Children's Hospital of Philadelphia), C. Labaki(Dana-Farber Cancer Institute)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
|Cell|2015|4.2k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k